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Objective: Malignant pleural mesothelioma (MPM) is an aggressive neoplasm with 
poor prognosis. Loss of BRCA-associated protein 1 (BAP1) protein expression as 
detected by immunohistochemistry (IHC) and homozygous deletion (HD) of the 9p21 
locus as detected by fluorescence in situ hybridization (FISH) permits differentiation of 
MPM from reactive mesothelial hyperplasia (RMH). We have previously reported that 
detecting the loss of methylthioadenosine phosphorylase (MTAP) using IHC is a 
surrogate assay for 9p21 FISH. Furthermore, enhancer of zeste homolog 2 (EZH2), 
which encodes a component of polycomb repressor complex 2 (PRC-2), has been 
overexpressed in various tumors as well as MPM. In the current study, we investigated 
whether EZH2 IHC assay, alone or in combination with BAP1 and MTAP IHC, is useful 
for distinguishing MPM from RMH. 
Materials and Methods: We examined IHC expression of EZH2, BAP1, and MTAP, and 
9p21 FISH in MPM (n = 38) and RMH (n = 29) and analyzed the sensitivity and 
specificity of each detection assay for distinguishing MPM from RMH. 
Results and Conclusion: EZH2, BAP1, and MTAP IHC, and 9p21 FISH were 
characterized by a 100% specificity each and 44.7%, 52.6%, 47.4%, and 65.8% 
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sensitivities, respectively. A combination of EZH2 and BAP1 IHC, and 9p21 FISH 
showed the greatest sensitivity (89.5%). Using IHC alone (EZH2, BAP1, and MTAP IHC) 
also yielded a good sensitivity of 86.9%; this level is high enough for routine diagnostics. 
There were no statistically significant associations between expression of EZH2 and that 
of other markers (BAP1 and MTAP IHC) or 9p21 HD. However, a high expression level 
of EZH2 was significantly associated with short survival (P = 0.025). In conclusion, 
adding a high expression level of EZH2 to a combination of BAP1 and MTAP loss, all 
detected by IHC, demonstrated useful for discriminating MPM from RMH. 
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deletion; IHC: immunohistochemistry; MPM: malignant pleural mesothelioma; MTPA 
IHC: methylthioadenosine phosphorylase as detected by immunohistochemistry; 
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Wilms’ tumor-1; CEA: carcinoembryonic antigen; EPP: extrapleural pneumonectomy; 
PD: pleurectomy and decortication; PcG: Polycomb group; PRC1: polycomb repressive 
complex 1; PH1: polyhomeotic 1; BMI1: B cell-specific Moloney murine leukemia 
virus integration site 1; CBX: chromobox; RING1A/1B: Ring finger protein 1A/1B; 
EED: embryonic ectoderm development; SUZ12: suppressor of zeste 12: RbAp48: 







     Malignant pleural mesothelioma (MPM) is the most common primary pleural 
tumor and aggressive neoplasm that arises from the mesothelium of the pleura. The 
prognosis is poor with a median survival of 9.2 to 11.2 months [1-3], although a better 
prognosis with a median survival of 5 years is reported for MPM with germline BAP1 
mutations [4, 5]. In the diagnosis of MPM, it is important to differentiate it from 
reactive mesothelial hyperplasia (RMH). RMH is a benign process, but sometimes 
resembles MPM histologically and cytologically [6-8]. Therefore, certain 
immunohistochemical markers, such as desmin, epithelial membrane antigen (EMA) [9, 
10], insulin-like growth factor mRNA binding protein 3 (IMP3) [10-12], glucose 
transporter-1 (GLUT-1) [12-15], and CD146 [12, 16, 17], have been used to distinguish 
RMH from MPM but these are not useful in an individual case [18]. 
Recently, two new markers: homozygous deletion (HD) of the 9p21 locus as 
detected by fluorescence in situ hybridization (FISH; 9p21 FISH) [18-21] and BRCA-1 
associated protein 1 (BAP1) [18, 19, 22-27] loss as detected by immunohistochemistry 
(IHC; BAP1 IHC) have been reported to be useful for distinguishing MPM from RMH 
with 100% specificity. The sensitivity of these markers individually is insufficient; 
however, their combination yields a high sensitivity [18-20, 27]. 
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BAP1 gene is located on the short arm of chromosome 3 (3p21.1), and has a role 
in cell proliferation and growth inhibition. BAP1 gene frequently shows inactivating 
mutations in 23-63.6% of MPM [22, 23, 28]. BAP1 nuclear staining is reliable evidence 
of BAP1 wild type, while cytoplasmic staining alone, no nuclear staining is reliable 
evidence of BAP1 mutation, since 99% of BAP1 mutations result in truncated BAP1 
proteins with loss of the carboxyterminus that contains the nuclear localization signal 
(NLS), or are mutations in the catalytic domain with consequent loss of the 
deubiquitylase activity of BAP1 required for nuclear translocation [23, 29, 30]. 
9p21 FISH cannot be performed by all laboratories because it requires highly 
skilled staff and is expensive. We have previously reported that methylthioadenosine 
phosphorylase (MTAP) as detected by IHC (MTAP IHC) is a good surrogate assay to 
9p21 FISH [31, 32]. In our previous study with epithelioid and biphasic MPM, MTAP 
loss was detected by IHC in 65%–75% of MPM with 9p21 HD. Furthermore, MTAP 
IHC distinguished malignant mesothelial proliferations from benign proliferations with 
a specificity of 100% and a sensitivity of 45.1% in tissue specimens and 43.2% in cell 
blocks from pleural effusions [31-33]. MTAP IHC showed 80% sensitivity and 100% 
specificity in differentiating sarcomatoid MPM from fibrous pleuritis [33]. Furthermore, 
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a combination of MTAP IHC and BAP1 IHC showed greater sensitivity (76.5–90%) in 
differentiating MPM from benign proliferations [31-33]. 
Enhancer of zeste homolog 2 (EZH2), which encodes a component of polycomb 
repressor complex 2 (PRC-2), has been overexpressed in MPM [34, 35]. EZH2 IHC 
showed high specificity in differentiating MPM from benign proliferations [35]. Thus, 
in the current study, we investigated whether a combination of three IHC methods 
(BAP1, MTAP, and EZH2) was effective for distinguishing MPM from RMH, 
compared with combinations of BAP1 IHC, EZH2 IHC, and 9p21 FISH.  
 
2. Materials and Methods 
2.1 Case Selection 
This study included 38 MPM and 29 RMH cases. All cases were obtained from 
the pleural lesion file (including consultation cases) of the Department of Pathology, 
Fukuoka University Hospital, Fukuoka, Japan, between 2001 and 2015. Histological 
mesothelioma diagnosis and classification were performed following the World Health 
Organization guidelines and classification for 2015. The mesothelial nature of each 
tumor was confirmed using IHC assays. Calretinin, podoplanin (D2-40), cytokeratin 
5/6, and Wilms’ tumor-1 (WT-1) were used as positive mesothelial markers. While 
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thyroid transcription factor-1 (TTF-1), Ber-EP4, and carcinoembryonic antigen (CEA) 
were used as negative markers.  
The study protocol was approved by the Ethics Committee of Fukuoka University 
Hospital (#11-7-11, 7/27/2011). Anonymous use of redundant tissues is part of the 
standard patient treatment agreement. 
 
2.2 IHC 
     For IHC, tissue was initially formalin-fixed, paraffin-embedded, and sliced into 4-
μm-thick sections. Endogenous peroxidase activity was then blocked using the blocking 
reagent included in the Dako EnVision Kit (Dako, California, USA) for 5 min at room 
temperature (RT) followed by epitope retrieval using pH 9.0 Tris-EDTA buffer for 20 or 
40 min at 95 °C. IHC was then performed using the following antibodies: anti-EZH2 
rabbit monoclonal antibody (clone D2C9; Cell Signaling Technology, Danvers, MA, 
USA; 1:100 dilution; 4 °C overnight), anti-BAP1 mouse monoclonal antibody (clone C-
4; Santa Cruz Biotechnology, Santa Cruz, CA, USA; 1:100 dilution; RT, 1 h), anti-
MTAP mouse monoclonal (clone 2G4; Abnova, Taipei, Taiwan; 1:100 dilution; RT 30 
min). Sections were then washed, incubated with ChemMate EnVision (Dako), and 
counterstained with hematoxylin. Specimens from breast tumors (for EZH2) and liver 
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tissue (for MTAP) served as positive controls. The surrounding stromal cells and 
lymphocytes were used as internal positive control cells for BAP1. 
Nuclear staining in mesothelial cells with the same as, or higher intensity than, 
positive controls or internal positive controls was regarded as positive in EZH2 or 
BAP1 IHC. In MTAP IHC, cytoplasmic expression with nuclear staining in mesothelial 
cells at the same as, or higher intensity than, the positive control was interpreted as 
positive. Cytoplasmic positivity was considered a non-specific reaction for BAP1 
staining. In each case, >500 tumor cells in five high power fields (×400) were evaluated, 
and the proportion of cells positive for staining was calculated. We set the cut-off value 
at 50% for MTAP and BAP1 IHC as described previously [31, 32]. For EZH2 IHC, 
staining was divided into two groups, low expression (proportion of cells <50%) or high 




The FISH studies were carried out on 4-μm-thick tissue sections as previously 
described [20, 31-33]. Sections were deparaffinized and rehydrated using descending 
alcohol dilutions, then washed with 2× saline-sodium citrate (SSC), exposed to 
pretreatment solution at 80 °C for 30 min (PathVysion HER2 DNA probe kit; Vysis, 
Downers Grove, IL, USA), and digested with pepsin solution (Sigma-Aldrich, Tokyo, 
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Japan) at 37 °C for 90 min. After refixation in 10% buffered formalin at RT for 10 min, 
the sections were treated with 2× SSC, dehydrated in ethanol, dried, and exposed to 
either of the two probes:190 kb Vysis LSI p16/CEP 9 (Abbott Japan, Tokyo, Japan) or 
57 kb SureFISH 9p21.3 CDKN2A (Agilent technologies, TX, USA). Both the probes 
and tissue sections were denatured at 80 °C for 10 min in the probe solution provided 
(Abbott Japan), followed by hybridization at 37 °C for 20 h in ThermoBrite (Abbott 
Japan). Finally, the tissue sections were washed with 2× SSC containing 0.3% Tween 20 
(Sigma, St. Louis, MO, USA) at 72 °C for 2 min and then with 2× SSC containing 0.1% 
Tween 20 at RT for 5 min. Nuclei were counterstained with 4’, 6-diamidino-2-
phenylindole (DAPI) in the antifade reagent (Vector Laboratories, Burlingame, CA, 
USA). Analyses were performed using a fluorescence microscope (Axio Imager Z1; 
Carl Zeiss MicroImaging, Jena, Germany) and Isis analysis system (MetaSystems, 
Altlussheim, Germany) equipped with filter sets with single and dual-band exciters for 
spectrum green, spectrum orange, and DAPI (UV 360 nm). 
HD was defined as the lack of both 9p21 signals. Heterozygous deletion was 
assumed when only one 9p21 signal was present or when the total number of 9p21 
signals did not exceed one-half the total number of centromeric signals. At least 100 
cells were scored for each case. Lymphocytes present in each preparation were used as 
internal negative controls and required to emit two signals per FISH probe. This result 
indicated that loss of the 9p21 signal was not due to pre-analytical factors (e.g., fixation 





2.4 Statistical analysis 
 
     Fisher’s exact test was performed to investigate the association between EZH2 
and other markers (BAP1 IHC, 9p21 FISH, and MTAP IHC). The Kaplan Meier method 
was performed for survival analyses, and the differences between survival curves were 
analyzed using the log-rank test. A P-value <0.05 was considered statistically 
significant. Statistical analyses were performed using IBM SPSS Statistics v24 (IBM, 




3.1 Clinicopathological characteristics 
 
Thirty-one of the 38 MPM cases were male and eight were female (M:F ratio: 
4.8:1). The mean age at diagnosis was 65.3 y (range 33–86 y). One of the 38 MPM 
cases was obtained via autopsy, 13 were obtained via biopsy, and the remainder were 
via surgery including extrapleural pneumonectomy (EPP) and pleurectomy and 
decortication (PD). Histology showed 27 epithelioid, 6 biphasic, and 5 sarcomatoid 
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MPM. Follow-up period ranged from 20 to 4248 d (mean 995 d). All of the 29 RMH 
cases were obtained from patients with bullae formation (all male; mean age 32.5 y, 
range: 18–78 y). 
 
3.2 IHCs and 9p21 FISH results 
 
     Representative results of IHC and 9p21 FISH in RMH and MPM are shown in 
Figure 1 and 2, respectively. EZH2 expression was visible in the nucleus. MTAP IHC 
showed positive reactivity in the cytoplasm as well as nucleus where MTAP expression 
is retained. MTAP loss was defined as MTAP reactivity in the cytoplasm and nucleus at 
an intensity lower than that in the positive control. BAP1 expression was observed in 
the nucleus, and BAP1 loss was defined as nuclear reactivity at an intensity lower than 
that in the internal positive control. BAP1 nuclear, together with a weaker cytoplasmic 
reactivity, reactivity is reliable evidence of BAP1 wild type, while cytoplasmic 
reactivity alone, no nuclear reactivity is reliable evidence of BAP1 mutation as 
described [23]. 
     The proportion of positivity for EZH2 in MPM cases showed a wide distribution 
from 4.5 to 93.9%, while that for EZH2 in RMH cases was confined to a range <40% 
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(Figure 3). According to the cut off value set at 50%, 44.7% of MPM cases were 
assessed as “high expression” while all RMH cases belonged to the “low expression” 
group. 
 
3.3 Sensitivity and specificity of detection assays for discriminating MPM from RMH 
 
     The sensitivity and specificity of each detection assay for discriminating MPM 
from RMH cases are summarized in Table 1. All of EZH2 IHC, BAP1 IHC, MTAP IHC, 
and 9p21 FISH were characterized by a 100% specificity and their sensitivities were 
44.7%, 52.6%, 47.4%, and 65.8%, respectively. The specificity was 100% for all 
combinations of IHC (EZH2, BAP1, and MTAP) and 9p21 FISH. Sensitivity was low 
with EZH2 IHC alone, but this increased when combined with other markers. Although 
a combination of EZH2 IHC, BAP1 IHC, and 9p21 FISH gave the highest sensitivity 
(89.5%), that of EZH2, BAP1, and MTAP, which was only a combination of 
immunostaining, was as high as 86.8%. 
. 




Table 2 shows the association of highly expressed EZH2 with other markers 
[BAP1 loss (IHC), 9p21 HD (FISH), and MTAP loss (IHC)]. Although highly expressed 
EZH2 and 9p21 HD showed a tendency to correlate, it was not statistically significant 
(P = 0.053). 
 
3.5 Survival analysis 
 
Survival analysis was performed in 37 MPM patients (27 epithelioid MPM, 5 
biphasic MPM, and 4 sarcomatoid MPM) available for follow-up (Figure 4). Overall 
survival (OS) was significantly longer in epithelioid MPM than sarcomatoid MPM 
(P = 0.041, Figure 4A). In all MPM cases the high EZH2 expression group had a 
significantly shorter OS than the low EZH2 expression group (P = 0.025, Figure 4B). 
However, when analyzed according to histological subtype, their prognostic effect was 
seen only in epithelioid MPM (P = 0.008, Figure 4C), and not in biphasic and 






This study demonstrated the diagnostic application of EZH2 IHC for 
differentiating MPM from RMH. Several recent studies describe the utility of 9p21 
FISH or BAP1 IHC for differentiating MPM from RMH [18-20, 36]. In the current 
study, sensitivity was low with EZH2 IHC alone, but when EZH2 IHC was combined 
with other markers, overall sensitivity increased. A combination of BAP1 IHC and 9p21 
FISH yielded a sensitivity of approximate 80%, whereas adding EZH2 IHC to this 
combination increased the overall sensitivity to about 90% (Table 1). Moreover, adding 
EZH2 IHC to a combination of BAP1 and MTAP IHC yielded a high sensitivity of 
86.8% and 100% specificity. Since 9p21 FISH cannot be performed in every facility, it 
is useful to have a diagnostic combination of IHC that can discriminate MPM from 
RMH.  
Based on the proportion of positively stained cells in each case of MPM and 
RMH (Figure 3), an actual clinical cut-off value in discrimination between MPM and 
RMH of 50% was considered reasonable also by our team as reported previously [35].  
The distribution of the proportion of positivity stained cells is different from those of 
BAP1 and MTAP [31]. BAP1 and MTAP exhibited a bimodal distribution of the 
proportion of positivity stained cells in MPM cases. However, for EZH2 there are some 
cases of positive cells among MPM patients showing around the cut-off value of 50%. 
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Thus, care should be taken in these cases. 
Polycomb group (PcG) proteins are critical epigenetic mediators of stem cell 
pluripotency. The two main families of PcG protein complexes are polycomb repressive 
complex 1 (PRC1) and PRC2. PRC1 consists of four core subunits: polyhomeotic 1 
(PH1), B-lymphoma Moloney murine leukemia virus insertion region-1 (BMI1), 
chromobox (CBX), and Ring finger protein 1A/1B (RING1A/1B). PRC2 consists of 
four core subunits: EZH2, embryonic ectoderm development (EED), suppressor of zeste 
12 (SUZ12), and retinoblastoma (Rb)-associated protein 48 (RbAp48). EZH2 has 
histone methyltransferase activity with H3K27 as its substrate, which catalyses to 
H3K27me2 or H3K27me3. H3K27me3 has been reported to recruit PRC1 via proteins 
of the CBX family. RING1A/1B induces the monoubiquitination of histone 2A lysin 
119 (H2AK119) [37]. Monoubiquitination of H2A is a critical mechanism in the control 
of initiation, elongation, and silencing of transcription and DNA repair [38]. On the 
other hand, the BAP1-ASXL1 complex has H2AK119ub deubiquitinase activity [39]. 
For this reason, BAP1 loss is considered to be related to a high expression of EZH2. A 
recent study described how BAP1 loss enhanced EZH2 expression and promoted 
proliferation of mesothelioma cell lines. Furthermore, it demonstrated that 
mesothelioma cells with BAP1 loss are sensitive to EZH2 pharmacologic inhibition 
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[40]. On the other hand, Sinozaki-Ushiku et al. showed no statistically significant 
association between BAP1 and EZH2 expression in MPM, suggesting that mechanisms 
underlying EZH2 overexpression and BAP1 loss may be distinct [35]. In this study, 
there was also no statistical association between high EZH2 expression and BAP1 loss 
(Table 2. P = 0.973). These findings suggest that EZH2 high expression in MPM does 
not necessarily coincide with BAP1 loss, possibility due to other mechanisms or tumor 
environment.  
This is the first report to demonstrate a relationship between highly expressed 
EZH2 and 9p21 homozygous deletion in MPM. This association showed a tendency to 
correlate, but was not statistically significant (Table 2. P = 0.053). There was no 
correlation between BAP1 IHC or MTAP IHC and highly expressed EZH2 (P = 0.973, 
P = 0.284). Therefore, this lack of correlation among these three IHCs (BAP1, MTAP, 
EZH2) enabled the combination to offer an increased sensitivity in differential diagnosis 
between MPM and RMH. A major limitation of our study was the relatively small 
sample size. Further studies are required to assess the usefulness of EZH2 IHC. 
High EZH2 overexpression has been reported in various cancers and particularly 
with the aggressiveness of tumors [41]. In this study, high EZH2 expression resulted in 
a significantly worse OS (P = 0.025). Pharmacological inhibition of EZH2/PRC2 by 3-
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Deazanplanocin A (DZNep), an S-adenosylhomocysteine (SAH) hydrolase inhibitor, has 
been shown to effectivity inhibit growth of MPM cells [34]. Phase II clinical trials of 
tazemetostat, an EZH2 inhibitor, have been initiated (ClinicalTrials.gov, 
NCT02860286). 
In conclusion, adding EZH2 to the diagnostic IHC panel for differentiating 
between MPM and RMH increased diagnostic sensitivity. Furthermore, highly 
expressed EZH2 was associated with poor prognosis.  
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Representative examples of H&E staining (A) and EZH2 (B), MTAP (C), and BAP1 
(D) immunostaining and 9p21 FISH (E) in RMH. Original magnifications ×400 (A–
D). (A): hyperplastic reactive mesothelial cells on the pleural surface, (B): low EZH2 
expression, (C): retained MTAP IHC in mesothelial cells, (D) retained BAP1 IHC in 
mesothelial cells, (E): Normal pattern, with two CEP-9 green centromeric signals and 
two 9p21 red signals in a single nucleus (white arrow). 
Figure 2. 
Representative examples of H&E staining (A) and EZH2 (B), MTAP (C), and BAP1 
(D) immunostaining, and 9p21 FISH (E) in MPM. Original magnifications ×400 (A–
D). (A): epithelioid MPM, (B): high EZH2 expression (nuclear staining), (C): loss of 
MTAP IHC in mesothelial cells (cytoplasmic/nuclear staining), (D) loss of BAP1 IHC 
in mesothelial cells (nuclear staining), (E): homozygous deletion, with two CEP-9 green 
centromeric signals and no 9p21 red signals in a single nucleus (white arrow). 
 
Figure 3. 
Proportion of cells expressing EZH2 in their nuclei in malignant pleural mesothelioma 
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(MPM) and reactive mesothelial hyperplasia (RMH). 
 
Figure 4. 
Overall survival (OS) curves for patients with MPM. (A) Histology (E-MPM, 
epithelioid malignant pleural mesothelioma; B-MPM, biphasic MPM; S-MPM, 
sarcomatoid MPM). (B) EZH2 status, (C) EZH2 status in only E-MPM, (D) EZH2 
status in B-MPM and S-MPM. 
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Table 1. Yoshimura M, et al. 
Table 1. Diagnostic application of detection assays to differentiate malignant pleural 
mesothelioma from reactive mesothelial hyperplasia 
 
 
   
 MPM 
(n = 38) 
RMH 





































EZH2 / 9p21 
High / HD 






EZH2 / BAP1 
High / Loss 






EZH2 / MTAP 
High / Loss 






BAP1 / 9p21  
Loss / HD 






BAP1 / MTAP 
Retained / Retained 






EZH2 / BAP1 / 9p21 
High / Loss / HD 






EZH2 / BAP1 / MTAP 
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Table 2. Yoshimura M, et al. 
 
Table 2. Association with high EZH2 expression and other markers (BAP1 IHC, 9p21 




 EZH2 low expression EZH2 high expression P-value 
BAP1 loss (-) 10 8 
0.973 
BAP1 loss (+) 11 9 
9p21 homozygous deletion (-) 10 3 
0.053 
9p21 homozygous deletion (+) 11 14 
MTAP loss (-) 6 7 
0.284 
MTAP loss (+) 13 7 
